Soluble CD206 in Metastatic Renal Cell Carcinoma
Author Information
Author(s): Kasper Munch Lauridsen, Holger Jon Møller, Mie Wolff Kristensen, Niels Fristrup, Frede Donskov, Marianne Hokland, Morten Nørgaard Andersen
Primary Institution: Aarhus University
Hypothesis
The study investigates the biomarker potential of soluble CD206 in patients with metastatic renal cell carcinoma.
Conclusion
High levels of serum soluble CD206 are associated with reduced overall survival in patients with intermediate-risk metastatic renal cell carcinoma.
Supporting Evidence
- Serum sCD206 was elevated in patients with intermediate-risk mRCC compared to healthy controls.
- High levels of serum sCD206 at baseline were a significant risk factor associated with reduced overall survival.
- Addition of sCD206 to the IMDC risk score improved prognostic separation of intermediate-risk patients.
Takeaway
This study found that a protein called soluble CD206 in the blood can help predict how well patients with kidney cancer will do, especially those with a certain level of risk.
Methodology
Serum soluble CD206 was measured in 88 patients with metastatic renal cell carcinoma and 20 healthy controls using an enzyme-linked immunosorbent assay.
Limitations
The study included an older treatment regimen and did not investigate the biological mechanisms linking sCD206 levels to clinical outcomes.
Participant Demographics
Patients included were either MSKCC favorable or intermediate risk, with a median age of 57 years.
Statistical Information
P-Value
p=0.002
Confidence Interval
95% CI: 1.12–1.67
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website